TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the announcement, the study is the result of the focus Lexaria has had for years on oral nicotine formulations as an alternative to vaping or smoking; the company noted that results from the study could lead to more rapid commercial adoption and distribution of its patented DehydraTECH(TM) absorption technology, which is designed to improve oral uptake. Statistics show that some 7 million people die every year from cigarette smoking, and alternatives for nicotine delivery are desperately needed. Lexaria’s DehydraTECH-nicotine is already patent granted for oral nicotine delivery in Australia and pending in numerous other countries. The company noted that its DehydraTECH-powered purified nicotine white pouch formulation contains no tobacco, and studies show that its DehydraTECH-nicotine can be 10 to 20 times fast and deliver up to tenfold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. LEXX’s NIC-H22-1 study is a human pharmacokinetic randomized, double-blinded, cross-over study with a minimum of 36 human volunteers who currently smoke cigarettes. The study objectives include determining the quantity of nicotine in blood at various time points and collecting vital-sign data, such as blood pressure, heart rate and respiratory rate; Lexaria will provide further updates and any relevant material findings as they become available.

To view the full press release, visit https://ibn.fm/SzVln

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is part of the InvestorBrandNetwork.